Allogeneic Cell Therapy Market Size, Share and Key Players Analysis 2026 to 2035
Segmentation of Allogeneic Cell Therapies Market :
Allogeneic Cell Therapies Market Revenue (US$ Mn) by Type of Cell Therapy
- Virus-Specific T-Cell
- Stem Cell
- Regulatory T-Cell
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Source of Cell
- Peripheral Blood
- Bone Marrow
- Umbilical Cord Blood
- Adipose Tissue
- Placenta
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Target Indication
- Bone Disorder
- Critical Limb Ischemia
- Crohn’s Disease
- Diabetic Foot Ulcer
- Graft versus Host Disease
- Leukemia
- Lymphoma
- Myelodysplastic Syndrome
- Cytomegalovirus Infection
- Others
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Therapeutic Area
- Oncological Disorders
- Neurological Disorders
- Musculoskeletal Disorder
- Autoimmune / Inflammatory Disorders
- Post-Transplant Infections
Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Region
- North America-
- US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America-
- Mexico
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Chapter 1.Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2.Executive Summary
Chapter 3.Global Allogeneic Cell Therapy Market Snapshot
Chapter 4.Global Allogeneic Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5.Market Segmentation 1: By Type of Cell Therapy Estimates & Trend Analysis
5.1. By Type of Cell Therapy & Market Share, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Type of Cell Therapy:
5.2.1. Virus-Specific T-Cell
5.2.2. Stem Cell
5.2.3. Regulatory T-Cell
Chapter 6.Market Segmentation 2: By Source of Cell Estimates & Trend Analysis
6.1. By Source of Cell & Market Share, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Type By Source of Cell:
6.2.1. Peripheral Blood
6.2.2. Bone Marrow
6.2.3. Umbilical Cord Blood
6.2.4. Adipose Tissue
6.2.5. Placenta
Chapter 7.Market Segmentation 3: By Target Indication Estimates & Trend Analysis
7.1. By Target Indication & Market Share, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Type By Target Indication:
7.2.1. Bone Disorder
7.2.2. Critical Limb Ischemia
7.2.3. Crohn’s Disease
7.2.4. Diabetic Foot Ulcer
7.2.5. Graft versus Host Disease
7.2.6. Leukemia
7.2.7. Lymphoma
7.2.8. Myelodysplastic Syndrome
7.2.9. Cytomegalovirus Infection
7.2.10. Others
Chapter 8.Market Segmentation 3: By Therapeutic Area Estimates & Trend Analysis
8.1. By Therapeutic Area & Market Share, 2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Type By Therapeutic Area:
8.2.1. Oncological Disorders
8.2.2. Neurological Disorders
8.2.3. Musculoskeletal Disorder
8.2.4. Autoimmune / Inflammatory Disorders
8.2.5. Post-Transplant Infections
Chapter 9.Allogeneic Cell Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Type of Cell Therapy, 2022-2035
9.1.2. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2022-2035
9.1.3. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2022-2035
9.1.4. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2022-2035
9.1.5. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2022-2035
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2022-2035
9.2.2. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2022-2035
9.2.3. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2022-2035
9.2.4. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2022-2035
9.2.5. Europe Allogeneic Cell Therapy Market revenue (US$ Million) by country, 2022-2035
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2022-2035
9.3.2. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2022-2035
9.3.3. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2022-2035
9.3.4. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2022-2035
9.3.5. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) by country, 2022-2035
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2022-2035
9.4.2. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2022-2035
9.4.3. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2022-2035
9.4.4. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2022-2035
9.4.5. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2022-2035
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, (US$ Million)
9.5.2. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2022-2035
9.5.3. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2022-2035
9.5.4. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2022-2035
9.5.5. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2022-2035
9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA
Chapter 10.Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. TCR² Therapeutics
10.2.2. TiGenix (Takeda)
10.2.3. Adaptimmune Therapeutics plc,
10.2.4. Adicet Bio, Inc.,
10.2.5. Allogene Therapeutics,
10.2.6. Allogene Therapeutics,
10.2.7. Artiva Biotherapeutic,
10.2.8. Atara Biotherapeutics,
10.2.9. Athersys, Inc.,
10.2.10. BioCardia Inc.,
10.2.11. Bluebird Bio,
10.2.12. BlueRock Therapeutics LP,
10.2.13. Bone Therapeutics,
10.2.14. Capricor Therapeutics,
10.2.15. Cell2Cure,
10.2.16. Cellectis,
10.2.17. Cellenkos,
10.2.18. Cellular Biomedicine Group,
10.2.19. Celularity,
10.2.20. Celyad,
10.2.21. Century Therapeutics,
10.2.22. CHABiotech,
10.2.23. CRISPR Therapeutics,
10.2.24. Cynata Therapeutics,
10.2.25. Cyto Therapeutics Pty Limited,
10.2.26. Fate Therapeutics,
10.2.27. Fate Therapeutics,
10.2.28. Fundamenta Therapeutics,
10.2.29. GammaDelta Therapeutics Limited,
10.2.30. GC Cell,
10.2.31. Hope Biosciences,
10.2.32. Immunity Bio,
10.2.33. Lineage Cell Therapeutics, Inc.,
10.2.34. MEDIPOST,
10.2.35. Mesoblast Ltd,
10.2.36. Nanjing Bioheng Biotech,
10.2.37. NantKwest,
10.2.38. Nkarta, Inc.,
10.2.39. Orca Bio,
10.2.40. Organogenesis Inc.,
10.2.41. Osiris Therapeutics, Inc.,
10.2.42. Pluristem Therapeutics Inc,
10.2.43. Poseida Therapeutics
10.2.44. Regeneus,
10.2.45. Stemedica Cell Technologies, Inc.,
10.2.46. Stempeutics
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Allogeneic Cell Therapy Market Size is valued at 1.33 Million in 2025 and is predicted to reach 4.49 Billion by the year 2035
The Allogeneic Cell Therapy Market is expected to grow at a 13.30% CAGR during the forecast period for 2026 to 2035.
Juno Therapeutics, Agios Pharmaceutical, Aurora BioPharma, Atara Biotherapeutics, AryoGen Biopharma, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd